Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently announced agreement with Searchlight Pharma will...
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
June 06, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to...
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 12, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610...
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 20, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an...
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
March 10, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in...
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
January 27, 2023 07:29 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two...
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
January 27, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3...
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 04:00 ET
|
Sol-Gel Technologies Ltd.
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel’s cash runway expected to extend through the end of the first quarter of 2024NESS ZIONA,...
Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
October 03, 2022 08:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded...
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022 06:00 ET
|
Sol-Gel Technologies Ltd.
Prescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel receives $3.5 million milestone payment from commercial partner Galderma Holding SA...